In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Eagle Pharmaceuticals, Inc.. Trade Record

NASDAQ:EGRX Eagle Pharmaceuticals, Inc. stock gains 15.69% Exit Mar 7, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart EGRX Feb 14, 2019, priceSeries
About Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Trade Information
Trade Type
LONG
ReliabilityScore™
95.40
Entry Date
Feb 14, 2019
Entry Price
40.53
Sell Date
Mar 7, 2019
Sell Price
46.89
Net Gain
15.69%
Hold Time
14 Trading Days